• Delayed hypersensitivity is a major mechanism of defense against various intracellular pathogens, including mycobacteria, fungi, and certain parasites, and it occurs in transplant rejection and tumor immunity. (medscape.com)
  • In this review, the phenomenon of delayed hypersensitivity is characterized briefly, and, based on recent reports, its apparent demonstration in immunity to Trichinella spiralis, Trichostrongylus colubriformis, Ancylostoma caninum, Fasciola hepatica , and Hymenolepis nana is presented. (ajtmh.org)
  • Simultaneous transfer of delayed hypersensitivity to diphtheria toxin and to tuberculin has been accomplished in eight consecutive instances in man using extracts from washed leucocytes taken from the peripheral blood of tuberculin-positive, Schick-negative donors who were highly sensitive ( i.e ., pseudoreactors) to purified diphtheria toxin and toxoid. (rupress.org)
  • One injection of this compound with wax intraperitoneally into guinea pigs results in a marked delayed cutaneous hypersensitivity, demonstrable by contact and intracutaneous test, and of long duration. (rupress.org)
  • Tumor-specific delayed hypersensitivity was transferred to peritoneal exudate cells obtained from unimmunized strain 2 guinea pigs after the peritoneal exudate cells were incubated with RNA-rich extracts from lymphoid tissues of syngeneic guinea pigs previously immunized to either of two antigenically distinct diethylnitrosamine-induced transplantable hepatomas. (aacrjournals.org)
  • Unlike the standard cytotoxic agents practitioners are familiar with, modern immunotherapies appear to work in a different and more delayed fashion. (mdpi.com)
  • DELZICOL® (mesalamine) delayed-release tablets are indicated for the maintenance of remission of ulcerative colitis in adults. (rxlist.com)
  • The data presented in Section 6.1 are from clinical trials conducted with mesalamine delayed-release tablets. (rxlist.com)
  • DELZICOL is bioequivalent to these mesalamine delayed-release tablets. (rxlist.com)
  • These highlights do not include all the information needed to use MESALAMINE DELAYED-RELEASE TABLETS safely and effectively. (nih.gov)
  • Mesalamine delayed-release tablets are a locally acting 5-aminosalicylic acid (5-ASA) indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. (nih.gov)
  • Patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of mesalamine delayed-release tablets. (nih.gov)
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as mesalamine delayed-release tablets that contain mesalamine or are converted to mesalamine. (nih.gov)
  • Mesalamine Delayed-release Tablets, 1.2 g are pale red-brown, oval-shaped, biconvex, bevel film-coated tablets debossed with the '711' on one side and plain on other side. (nih.gov)